Figure 2 | Scientific Reports

Figure 2

From: The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients

Figure 2

Association of circulating NEP with all-cause mortality. Overall survival rates for (A) the total cohort of treatment-naïve cancer patients (n = 555) according to tertiles of circulating NEP (p = 0.545 between all groups, log-rank test) and stratified to the most common malignant disease entities, i.e. (B) myelodysplastic disease, (C) myeloproliferative disease, (D) breast cancer, (E) lung cancer and (F) gastrointestinal malignancies.

Back to article page